Preliminary evidence for preserved synaptic density in late-life depression
Open accessThe DOI matches its Crossref record; 64 of the 64 references it cites were found in a registry or an index; 9 of the 44 sources its claims cite were checked for support.
Abstract
Late-life depression has been consistently associated with lower gray matter volume, the origin of which remains largely unexplained. Recent in-vivo PET findings in early-onset depression and Alzheimer’s Disease suggest that synaptic deficits contribute to the pathophysiology of these disorders and may therefore contribute to lower gray matter volume in late-life depression. Here, we investigate synaptic density in vivo for the first time in late-life depression using the synaptic vesicle glycoprotein 2A receptor radioligand 11 C-UCB-J. We included 24 currently depressed adults with late-life depression (73.0 ± 6.2 years, 16 female, geriatric depression scale = 19.5 ± 6.8) and 36 age- and gender-matched healthy controls (70.4 ± 6.2 years, 21 female, geriatric depression scale = 2.7 ± 2.9) that underwent simultaneous 11 C-UCB-J positron emission tomography (PET) and 3D T1- and T2-FLAIR weighted magnetic resonance (MR) imaging on a 3-tesla PET-MR scanner. We used analyses of variance to test for 11 C-UCB-J binding and gray matter volumes differences in regions implicated in depression. The late-life depression group showed a trend in lower gray matter volumes in the hippocampus (p = 0.04), mesial temporal (p = 0.02) and prefrontal cortex (p = 0.02) compared to healthy control group without surviving correction for multiple comparison. However, no group differences in 11 C-UCB-J binding were found in these regions nor were any associations between 11 C-UCB-J and depressive symptoms. Our data suggests that, in contrast to Alzheimer’s Disease, lower gray matter volume in late-life depression is not associated with synaptic density changes. From a therapeutic standpoint, preserved synaptic density in late-life depression may be an encouraging finding.
Overview
CoChat Summary
TL;DR
In this first in vivo study of synaptic density in late-life depression, 11C-UCB-J PET showed no evidence of altered synaptic density in depression-implicated brain regions despite trend-level lower gray matter volumes. The authors conclude that lower gray matter volume in late-life depression may not be associated with synaptic loss, unlike Alzheimer’s disease.
Key findings
- The LLD group showed trend-level lower gray matter volume versus controls in hippocampus (p = 0.04), mesial temporal cortex (p = 0.02), and prefrontal cortex (p = 0.02), but none survived Bonferroni correction (α = 0.008).
- No group differences were found in 11C-UCB-J binding in hippocampus, mesial temporal, anterior cingulate, lateral temporal, prefrontal, or parietal regions; all p-values were ≥ 0.05.
- Within the LLD group, 11C-UCB-J SUVR did not correlate with depression severity on GDS or MADRS in any VOI; some inverse correlations with MMSE appeared in prefrontal (r = −0.48, p = 0.02) and parietal (r = −0.44, p = 0.03) regions but did not survive Bonferroni correction.
- Post hoc mediation analysis found the association between LLD and gray matter volume was not mediated by synaptic density.
Methods
- Cross-sectional case-control study including 24 currently depressed adults with LLD (73.0 ± 6.2 years, 16 female, GDS = 19.5 ± 6.8) and 36 age- and gender-matched healthy controls (70.4 ± 6.2 years, 21 female, GDS = 2.7 ± 2.9).
- Participants underwent simultaneous 11C-UCB-J PET and 3D T1- and T2-FLAIR-weighted MR imaging on a 3-tesla PET-MR scanner; SUVR images used centrum semiovale as reference region with partial volume correction.
- Analyses used ANCOVA for TIV-normalized gray matter volumes with age as covariate, ANOVA for 11C-UCB-J SUVR, and Pearson correlations for clinical associations; significance was claimed after Bonferroni correction for multiple comparisons (α = 0.008), with α = 0.05 reported as trend.
Limitations
- The paper states that T1-weighted MR segmentation is prone to artefacts; SUVR is a simplified quantification method validated in healthy aging and AD but not in LLD; white matter lesions may have biased results; and 11C-UCB-J as a proxy for synaptic density requires further validation.
- The authors also note that little is known about how psychotropic medication, including antidepressants and benzodiazepines, affects 11C-UCB-J binding, and that type II errors due to sample size and heterogeneity cannot be excluded.
- Evident from the text: all but one LLD patient were medicated, 12 took benzodiazepines, and the main imaging findings did not survive correction for multiple comparisons, so the results are preliminary.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
7 Valid · 1 Not valid · 28 Not checked · 57 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Hence, imaging of SV2A using 11C-UCB-J positron emission tomography (PET) provides a suitable proxy for synaptic density in both physiological and pathological conditions [21].”
§ Preliminary evidence for preserved synaptic density in late-life depression > Introduction
What the sources say
- Partly supportedcites [21] Serrano ME Kim E Petrinovic MM Turkheimer F Cash D Imaging Synaptic Density: The Next Holy Grail of Neuroscience? Front Neurosci 2022 16 796129 10.3389/fnins.2022.796129 35401097 PMC8990757 sourceExperimental — accuracy not yet measured
Our copy does treat [11C]UCB-J/SV2A PET as the in vivo synaptic-density approach used across both normal and diseased brain (Assessing Synaptic Density by PET section; Table 2 in the Discussion lists 'allows the in vivo evaluation of synaptic density... validated to be used in both animals and humans'; examples include healthy-volunteer vs AD comparisons with [11C]UCB-J and clinical/preclinical disease studies), so the scope of the claim is reflected. What the source does not support is the unqualified 'suitable proxy': the Abstract calls SV2A 'a putative synaptic density marker' with 'limited specificity', the PET section offers only 'potential markers of synaptic density' (Smart et al. 2021), and the PET 'Limitations' subsection states SV2A radiotracer results 'although promising must be taken with caution since they rely on three aspects: (1) the reliability of using SV2A as synaptic density marker in a specific disease, (2) the variability of SV2A expression due to external stimulus, and (3) the ability of the radiotracer to bind to the SV2A protein'. The citing sentence therefore converts the review's hedged, disease-dependent position into a settled statement of validity in pathological conditions. (LLM, conf=0.75)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The only other study that has investigated 11C-UCB-J in depression focused on unmedicated depressed MDD/PTSD adults under the age of 60 [22].”
§ Preliminary evidence for preserved synaptic density in late-life depression > Discussion
What the sources say
- Partly supportedcites [22] Holmes SE Scheinost D Finnema SJ Naganawa M Davis MT DellaGioia N Lower synaptic density is associated with depression severity and network alterations Nat Commun 2019 10 1529 10.1038/s41467-019-09562-7 30948709 PMC6449365 sourceExperimental — accuracy not yet measured
Holmes et al. (2019) is indeed a [11C]UCB-J PET study in depression: Methods > Participants reports 'Twenty-six unmedicated clinical subjects ... medication-free for at least 4 months' comprising 11 MDD, 5 PTSD and 10 comorbid MDD/PTSD plus 21 matched healthy controls, and the Introduction frames it as the first in vivo synaptic-density study in living humans with MDD and PTSD. However, our copy nowhere states an upper age limit or age-range inclusion criterion ('under the age of 60'); it gives only mean ages (clinical 39.2 ± 12.1, HC 44.5 ± 15.4, Table 1), which does not establish a cap below 60 — indeed the HC SD implies some participants could exceed 60. The 'only other study' exclusivity is the citing authors' framing and is not tested here. (LLM, conf=0.72)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Gray matter volume decrease is well described in aging [42], but it is not necessarily correlated with a loss of neurons [43] or synaptic density decrease (as measured by 11C-UCB-J) [35].”
§ Preliminary evidence for preserved synaptic density in late-life depression > Discussion
What the sources say
- Supportedcites [43] Morrison JH Baxter MG The ageing cortical synapse: hallmarks and implications for cognitive decline Nat Rev Neurosci 2012 13 240 50 10.1038/nrn3200 22395804 PMC3592200 source
The Synaptic Aging in the Prefrontal Cortex section reports an age-related decrease in dorsolateral prefrontal cortex volume without significant neuron loss, directly supporting the part of the sentence attributed to this source [43]. The separate claim about synaptic density measured by 11C-UCB-J is attributed to [35], not this paper. (LLM, conf=0.92)
- Supportedcites [35] Michiels L Delva A Van Aalst J Ceccarini J Vandenberghe W Vandenbulcke M Synaptic density in healthy human aging is not influenced by age or sex: a 11C-UCB-J PET study NeuroImage 2021 232 117877 10.1016/j.neuroimage.2021.117877 33639258 source
The abstract (p. 1) reports age-related grey-matter changes but no significant decrease in ¹¹C-UCB-J binding after partial-volume correction in the voxel-based analysis. The Discussion (p. 4) interprets this as stable cortical synaptic density with healthy aging, while noting a small decrease in the caudate nucleus. Citation [35] supports the synaptic-density part of the sentence; the neuron-loss part is attributed to a different citation. (LLM, conf=0.91)
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Within the LLD group, age and depression severity did not correlate with 11C-UCB-J SUVR in any of the VOIs.”
§ Preliminary evidence for preserved synaptic density in late-life depression > Results > Clinical correlations in LLD
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“None of the ANCOVA results survived Bonferroni correction (Fig. 2A, supplementary table 2A).”
§ Preliminary evidence for preserved synaptic density in late-life depression > Results > Volumetric group differences
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
22 more claims
Create a free account to see all 93 claims and to verify the 35 references still open.
- Probably not a substantial claim. 49
- It may state two separate claims as one. 26
- The quote only partly states this claim. 2
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“recent work by Vande Casteele and colegues [159] did not observe a synaptic deficit in older individuals (73.0 ± 6.2 years) with depression or corelations with clinical outcomes.”
From Challenges and rewards of in vivo synaptic density imaging, and its application to the study of depression (2025) · cites this paper as [159]
In the citing paper
“the null findings and discrepancy from our report in younger individuals could also be, in part, due to differences in the PET methodology, including the use of CS as a reference region.”
From Challenges and rewards of in vivo synaptic density imaging, and its application to the study of depression (2025) · cites this paper as [159]
Statistics that don’t add up
Each reported p-value recomputed from its test statistic and degrees of freedom.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
“F(1,57) = 6.33, p = 0.02”
§ Preliminary evidence for preserved synaptic density in late-life depression > Results > Volumetric group differences
Reported p = .02 · recomputed p = .015
Statistics recomputed
Every reported test result, recomputed from its test statistic and degrees of freedom. A result shows as not adding up only once an independent check has confirmed it.
- Doesn’t add upF(1, 57) = 6.33reported p = .02 · recomputed p = .015
“F(1,57) = 6.33, p = .02”
- ConsistentF(1, 57) = 4.56reported p = .04 · recomputed p = .037
“F(1,57) = 4.56, p = .04”
- ConsistentF(1, 57) = 6.11reported p = .02 · recomputed p = .016
“F(1,57) = 6.11, p = .02”
- ConsistentF(1, 57) = 0.55reported p = .46 · recomputed p = .461
“F(1,57) = 0.55, p = .46”
- ConsistentF(1, 57) = 4.02reported p = .05 · recomputed p = .050
“F(1,57) = 4.02, p = .05”
7 more recomputed tests
Create a free account to see every test the Stats check recomputed.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Preliminary evidence for preserved synaptic density in late-life depression > Results > Clinical correlations in LLD
“the MMSE (r = 0.45, p = 0.03)”
§ Preliminary evidence for preserved synaptic density in late-life depression > Results > Clinical correlations in LLD
“| Parietal | −0.62, 0.001* | 0.45, 0.03 | 0.44, 0.03 | −0.45, 0.03 | −0.12, 0.61 |”
Citations
Cites
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
Hirono, N., Mori, E., Ikejiri, Y., Imamura, T., Shimomura, T., Hashimoto, M., Yamashita, H., & Ikeda, M. (1997) · Brain and nerve · Cited by 21,038
Kok, J. S., Berg, I. J., & Scherder, E. J. A. (2013) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000353441 · Cited by 20,589
Older Adults' Reasons for Using Technology while Aging in Place
Peek, S. T. M., Luijkx, K. G., Rijnaard, M. D., Nieboer, M. E., van der Voort, C. S., Aarts, S., van Hoof, J., Vrijhoef, H. J. M., & Wouters, E. J. M. (2016) · Gerontology · doi:10.1159/000430949 · Cited by 19,690
Sensitivity and False Alarm Rate of a Fall Sensor in Long-Term Fall Detection in the Elderly
Kangas, M., Korpelainen, R., Vikman, I., Nyberg, L., & Jämsä, T. (2015) · Gerontology · doi:10.1159/000362720 · Cited by 18,909
Development and validation of a geriatric depression screening scale: a preliminary report
Yesavage, J. A., Brink, T. L., Rose, T. L., Lum, O., Huang, V., Adey, M., & Leirer, V. O. (1982) · Journal of Psychiatric Research · doi:10.1016/0022-3956(82)90033-4 · Cited by 15,025 · cited 1×
“We used the Geriatric Depression Scale (GDS, 30 items) [24] and the Montgomery-Asberg Depression Rating Scale (MADRS) [25] to assess depression severity, the Mini-Mental State Examination (MMSE) [26] to assess global cognitive function and the Rey Auditory Verbal Learning Test [27] immediate recall…”
MethodA new depression scale designed to be sensitive to change
Montgomery, S. A., & Åsberg, M. (1979) · British Journal of Psychiatry · doi:10.1192/bjp.134.4.382 · Cited by 13,962 · cited 1×
“We used the Geriatric Depression Scale (GDS, 30 items) [24] and the Montgomery-Asberg Depression Rating Scale (MADRS) [25] to assess depression severity, the Mini-Mental State Examination (MMSE) [26] to assess global cognitive function and the Rey Auditory Verbal Learning Test [27] immediate recall…”
MethodNIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease
Jack, C. R., Bennett, D. A., Blennow, K., Carrillo, M. C., Dunn, B., Haeberlein, S. B., Holtzman, D. M., Jagust, W., Jessen, F., Karlawish, J., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.02.018 · Cited by 10,537
Domingos da Silveira da Luz, A. C., Pereira Dias, G., do Nascimento Bevilaqua, M. C., Cocks, G., Gardino, P. F., Thuret, S., & Nardi, A. E. (2013) · Neuropsychobiology · doi:10.1159/000353269 · Cited by 3,995
Cognitive Stimulation in Patients with Dementia: Randomized Controlled Trial
Mapelli, D., Di Rosa, E., Nocita, R., & Sava, D. (2013) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000353457 · Cited by 3,453
Brain charts for the human lifespan
Bethlehem, R. A. I., Seidlitz, J., White, S. R., Vogel, J. W., Anderson, K. M., Adamson, C., Adler, S., Alexopoulos, G. S., Anagnostou, E., Areces-Gonzalez, A., et al. (2022) · Nature · doi:10.1038/s41586-022-04554-y · Cited by 1,794
Synaptic plasticity and depression: new insights from stress and rapid-acting antidepressants
Duman, R. S., Aghajanian, G. K., Sanacora, G., & Krystal, J. H. (2016) · Nature Medicine · doi:10.1038/nm.4050 · Cited by 1,750
Smaller hippocampal volume predicts pathologic vulnerability to psychological trauma
Gilbertson, M. W., Shenton, M. E., Ciszewski, A., Kasai, K., Lasko, N. B., Orr, S. P., & Pitman, R. K. (2002) · Nature Neuroscience · doi:10.1038/nn958 · Cited by 1,635
Peripheral cytokine and chemokine alterations in depression: a meta‐analysis of 82 studies
Köhler, C. A., Freitas, T. H., Maes, M., de Andrade, N. Q., Liu, C. S., Fernandes, B. S., Stubbs, B., Solmi, M., Veronese, N., Herrmann, N., et al. (2017) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12698 · Cited by 1,443 · cited 1×
“For example, LLD is associated with increased vascular pathology [1], enhanced molecular and senescent changes [2], increased neuroin-fl ammation [3], and lower gray matter volume (GMV) [4].”
BackgroundDepression and risk of developing dementia
Byers, A. L., & Yaffe, K. (2011) · Nature Reviews Neurology · doi:10.1038/nrneurol.2011.60 · Cited by 1,265 · cited 1×
“Importantly, LLD is associated with a twofold risk of developing dementia [10].”
BackgroundMechanisms of ketamine action as an antidepressant
Zanos, P., & Gould, T. D. (2018) · Molecular Psychiatry · doi:10.1038/mp.2017.255 · Cited by 1,127 · cited 1×
“Emerging antidepressant therapies, including ketamine [12], psilocybin [13] and electroconvulsive therapy [14] are thought to enhance synaptic plasticity and have shown promising clinical results in depression [15, 16].”
BackgroundThe ageing cortical synapse: hallmarks and implications for cognitive decline
Morrison, J. H., & Baxter, M. G. (2012) · Nature Reviews Neuroscience · doi:10.1038/nrn3200 · Cited by 965
A meta-analysis of depression severity and cognitive function
McDermott, L. M., & Ebmeier, K. P. (2009) · Journal of Affective Disorders · doi:10.1016/j.jad.2009.04.022 · Cited by 956
Prefrontal–hippocampal interactions in episodic memory
Eichenbaum, H. (2017) · Nature Reviews Neuroscience · doi:10.1038/nrn.2017.74 · Cited by 870
Decreased expression of synapse-related genes and loss of synapses in major depressive disorder
Kang, H. J., Voleti, B., Hajszan, T., Rajkowska, G., Stockmeier, C. A., Licznerski, P., Lepack, A., Majik, M. S., Jeong, L. S., Banasr, M., et al. (2012) · Nature Medicine · doi:10.1038/nm.2886 · Cited by 808
Psilocybin induces rapid and persistent growth of dendritic spines in frontal cortex in vivo
Shao, L.-X., Liao, C., Gregg, I., Davoudian, P. A., Savalia, N. K., Delagarza, K., & Kwan, A. C. (2021) · Neuron · doi:10.1016/j.neuron.2021.06.008 · Cited by 626
Mechanisms and treatment of late-life depression
Alexopoulos, G. S. (2019) · Translational Psychiatry · doi:10.1038/s41398-019-0514-6 · Cited by 592
Imaging synaptic density in the living human brain
Finnema, S. J., Nabulsi, N. B., Eid, T., Detyniecki, K., Lin, S.-F., Chen, M.-K., Dhaher, R., Matuskey, D., Baum, E., Holden, D., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf6667 · Cited by 575 · cited 1×
“…density might therefore shed light on potential neurodegenerative patterns in LLD. Quantifying synaptic density in humans in vivo recently became possible with the advent of radioligands targeting the synaptic vesicle glycoprotein 2A (SV2A), a ubiquitous presynaptic transmembrane protein [20].”
BackgroundLower synaptic density is associated with depression severity and network alterations
Holmes, S. E., Scheinost, D., Finnema, S. J., Naganawa, M., Davis, M. T., DellaGioia, N., Nabulsi, N., Matuskey, D., Angarita, G. A., Pietrzak, R. H., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-09562-7 · Cited by 484
Increased global integration in the brain after psilocybin therapy for depression
(2022) · doi:10.1038/s41591-022-01744-z · Cited by 445 · cited 1×
“Emerging antidepressant therapies, including ketamine [12], psilocybin [13] and electroconvulsive therapy [14] are thought to enhance synaptic plasticity and have shown promising clinical results in depression [15, 16].”
BackgroundBahji, A., Vazquez, G. H., & Zarate, C. A. (2021) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.09.071 · Cited by 408
Neuropsychiatric symptoms in Alzheimer's disease: Past progress and anticipation of the future
Geda, Y. E., Schneider, L. S., Gitlin, L. N., Miller, D. S., Smith, G. S., Bell, J., Evans, J., Lee, M., Porsteinsson, A., Lanctôt, K. L., et al. (2013) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2012.12.001 · Cited by 378
Whitwell, J. L., Crum, W. R., Watt, H., & Fox, N. C. (2001) · PubMed · Cited by 367
The Vascular Depression Hypothesis: 10 Years Later
Alexopoulos, G. S. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.09.006 · Cited by 252 · cited 1×
“For example, LLD is associated with increased vascular pathology [1], enhanced molecular and senescent changes [2], increased neuroin-fl ammation [3], and lower gray matter volume (GMV) [4].”
BackgroundGeerlings, M. I., den Heijer, T., Koudstaal, P. J., Hofman, A., & Breteler, M. M. B. (2008) · Neurology · doi:10.1212/01.wnl.0000308937.30473.d1 · Cited by 248 · cited 1×
“With regard to the latter, magnetic resonance imaging (MR) studies of late-life depression consistently report lower GMV in brain regions also associated with Alzheimer ’ s Disease (AD) pathology, such as the frontal [5], temporal [6] and parietal regions [7].”
BackgroundTargeting the Synapse in Alzheimer’s Disease
Jackson, J., Jambrina, E., Li, J., Marston, H., Menzies, F., Phillips, K., & Gilmour, G. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00735 · Cited by 215
A Systematic Review and Meta-Analysis of Magnetic Resonance Imaging Studies in Late-Life Depression
Sexton, C. E., Mackay, C. E., & Ebmeier, K. P. (2013) · The American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2012.10.019 · Cited by 210 · cited 2×
“We therefore conducted a cross-sectional case-control study in older adults that investigated synaptic density and GMV in brain regions implicated in LLD [4].”
BackgroundMethodFinding the Elusive Psychiatric “Lesion” With 21st-Century Neuroanatomy: A Note of Caution
Weinberger, D. R., & Radulescu, E. (2016) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2015.15060753 · Cited by 173
Cellular correlates of cortical thinning throughout the lifespan
Vidal-Pineiro, D., Parker, N., Shin, J., French, L., Grydeland, H., Jackowski, A. P., Mowinckel, A. M., Patel, Y., Pausova, Z., Salum, G., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-78471-3 · Cited by 154
Gray Matter Changes in Late Life Depression—a Structural MRI Analysis
Andreescu, C., Butters, M. A., Begley, A. E., Rajji, T. K., Wu, M., MELTZER, C. C., Reynolds, C. F., & Aizenstein, H. J. (2007) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301655 · Cited by 153
Brain grey matter volume alterations in late-life depression
Du, M., Liu, J., Chen, Z., Huang, X., Li, J., Kuang, W., Yang, Y., Zhang, W., Zhou, D., Bi, F., et al. (2014) · Journal of Psychiatry and Neuroscience · doi:10.1503/jpn.130275 · Cited by 140 · cited 1×
“With regard to the latter, magnetic resonance imaging (MR) studies of late-life depression consistently report lower GMV in brain regions also associated with Alzheimer ’ s Disease (AD) pathology, such as the frontal [5], temporal [6] and parietal regions [7].”
BackgroundSynaptic Vesicle Glycoprotein 2A: Features and Functions
Rossi, R., Arjmand, S., Bærentzen, S. L., Gjedde, A., & Landau, A. M. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.864514 · Cited by 123
Koole, M., van Aalst, J., Devrome, M., Mertens, N., Serdons, K., Lacroix, B., Mercier, J., Sciberras, D., Maguire, P., & Van Laere, K. (2019) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-018-4119-8 · Cited by 118
Self-citationOusdal, O. T., Brancati, G. E., Keßler, U., Erchinger, V. J., Dale, A. M., Abbott, C., & Oltedal, L. (2021) · Biological Psychiatry · doi:10.1016/j.biopsych.2021.05.023 · Cited by 112 · cited 1×
“Emerging antidepressant therapies, including ketamine [12], psilocybin [13] and electroconvulsive therapy [14] are thought to enhance synaptic plasticity and have shown promising clinical results in depression [15, 16].”
BackgroundWhole-brain atrophy rate in Alzheimer disease: Identifying fast progressors
Sluimer, J. D., Vrenken, H., Blankenstein, M. A., Fox, N. C., Scheltens, P., Barkhof, F., & van der Flier, W. M. (2008) · Neurology · doi:10.1212/01.wnl.0000311446.61861.e3 · Cited by 110
Imaging of Synaptic Density in Neurodegenerative Disorders
Carson, R. E., Naganawa, M., Toyonaga, T., Koohsari, S., Yang, Y., Chen, M.-K., Matuskey, D., & Finnema, S. J. (2022) · Journal of Nuclear Medicine · doi:10.2967/jnumed.121.263201 · Cited by 104
Alzheimer’s Disease and Inflammaging
Kosyreva, A., Sentyabreva, A., Tsvetkov, I., & Makarova, O. (2022) · Brain Sciences · doi:10.3390/brainsci12091237 · Cited by 98
In vivo synaptic density loss is related to tau deposition in amnestic mild cognitive impairment
Vanhaute, H., Ceccarini, J., Michiels, L., Koole, M., Sunaert, S., Lemmens, R., Triau, E., Emsell, L., Vandenbulcke, M., & Van Laere, K. (2020) · Neurology · doi:10.1212/wnl.0000000000009818 · Cited by 88 · cited 2×
“Interestingly, synapse loss is an early feature of mesial temporal atrophy in AD [17, 18], possibly explaining the clinical overlap between LLD and AD [19].”
BackgroundMethodSelf-citationImaging the effect of ketamine on synaptic density (SV2A) in the living brain
Holmes, S. E., Finnema, S. J., Naganawa, M., DellaGioia, N., Holden, D., Fowles, K., Davis, M., Ropchan, J., Emory, P., Ye, Y., et al. (2022) · Molecular Psychiatry · doi:10.1038/s41380-022-01465-2 · Cited by 78
Cellular abnormalities in depression: evidence from postmortem brain tissue
Stockmeier, C. A., & Rajkowska, G. (2004) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2004.6.2/cstockmeier · Cited by 67
Imaging Synaptic Density: The Next Holy Grail of Neuroscience?
Serrano, M. E., Kim, E., Petrinovic, M. M., Turkheimer, F., & Cash, D. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.796129 · Cited by 67
Rakić, M., Vercruyssen, S., Eyndhoven, S. V., de la Rosa, E., Jain, S., Huffel, S. V., Maes, F., Smeets, D., & Sima, D. M. (2021) · NeuroImage Clinical · doi:10.1016/j.nicl.2021.102707 · Cited by 66 · cited 2×
“White matter (periventricular and deep) lesions (WML) were delineated automatically with an AI based algorithm implemented in icoBrain [28] applied to T1-and T2 FLAIR-weighted images before manual revision by a neurologist.”
MethodInfluentialCox, S. R., Harris, M. A., Ritchie, S. J., Buchanan, C. R., Valdés Hernández, M. C., Corley, J., Taylor, A. M., Madole, J. W., Harris, S. E., Whalley, H. C., et al. (2021) · Molecular Psychiatry · doi:10.1038/s41380-020-00975-1 · Cited by 60
Boccia, M., Acierno, M., & Piccardi, L. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-142955 · Cited by 59 · cited 1×
“The extent of GMV changes, however, are more pronounced in AD [8, 9].”
BackgroundSynaptic density in healthy human aging is not influenced by age or sex: a 11C-UCB-J PET study
Michiels, L., Delva, A., van Aalst, J., Ceccarini, J., Vandenberghe, W., Vandenbulcke, M., Koole, M., Lemmens, R., & Laere, K. V. (2021) · NeuroImage · doi:10.1016/j.neuroimage.2021.117877 · Cited by 59
Self-citationSchramm, G., Koole, M. J. B., Willekens, S. M. A., Rezaei, A., Weehaeghe, D. V., Delso, G., Peeters, R. R., Mertens, N., Nuyts, J. L., & Laere, K. V. (2019) · Frontiers in Physics · doi:10.3389/fphy.2019.00211 · Cited by 53 · cited 1×
“By use of an iterative ordered-subset expectation maximization algorithm (28 sub-sets, 4 iterations) 6 PET frames of 5 minutes were reconstructed incorporating time of fl ight data, as well as decay, scatter, and a validated zero echo time (ZTE) attenuation correction [29].”
MethodSelf-citationVanderlinden, G., Ceccarini, J., Vande Casteele, T., Michiels, L., Lemmens, R., Triau, E., Serdons, K., Tournoy, J., Koole, M., Vandenbulcke, M., et al. (2022) · Molecular Psychiatry · doi:10.1038/s41380-022-01672-x · Cited by 47
Self-citationSmart, K., Liu, H., Matuskey, D., Chen, M.-K., Torres, K., Nabulsi, N., Labaree, D., Ropchan, J., Hillmer, A. T., Huang, Y., et al. (2021) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x20946198 · Cited by 42
Diniz, B. S., Mulsant, B. H., Reynolds, C. F., Blumberger, D. M., Karp, J. F., Butters, M. A., Mendes-Silva, A. P., Vieira, E. L., Tseng, G., & Lenze, E. J. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.19678 · Cited by 39 · cited 1×
“For example, LLD is associated with increased vascular pathology [1], enhanced molecular and senescent changes [2], increased neuroin-fl ammation [3], and lower gray matter volume (GMV) [4].”
BackgroundValidity and diagnostic accuracy of an alternate form of the rey auditory verbal learning test
Ryan, J., & Geisser, M. E. (1986) · Archives of Clinical Neuropsychology · doi:10.1016/0887-6177(86)90027-2 · Cited by 38 · cited 1×
“…[24] and the Montgomery-Asberg Depression Rating Scale (MADRS) [25] to assess depression severity, the Mini-Mental State Examination (MMSE) [26] to assess global cognitive function and the Rey Auditory Verbal Learning Test [27] immediate recall trials (RAVLT-IR) as a proxy for episodic memory.”
MethodMertens, N., Michiels, L., Vanderlinden, G., Vandenbulcke, M., Lemmens, R., Laere, K. V., & Koole, M. (2022) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x221076023 · Cited by 38 · cited 1×
“Since expected GMV differences might induce partial volume effects [30], we corrected images with an validated inhouse region-based voxel-wise partial volume correction (RBV PVC) algorithm (see Mertens et al. [31]. for a detailed Fig.”
MethodSelf-citationPartial volume correction analysis for 11C-UCB-J PET studies of Alzheimer's disease
Lu, Y., Toyonaga, T., Naganawa, M., Gallezot, J.-D., Chen, M.-K., Mecca, A. P., van Dyck, C. H., & Carson, R. E. (2021) · NeuroImage · doi:10.1016/j.neuroimage.2021.118248 · Cited by 37
Takamiya, A., Casteele, T. V., Koole, M. J. B., Winter, F. D., Bouckaert, F., den Stock, J. V., Sunaert, S. G., Dupont, P. J., Vandenberghe, R. R., Laere, K. V., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-95206-0 · Cited by 30 · cited 1×
“Interestingly, synapse loss is an early feature of mesial temporal atrophy in AD [17, 18], possibly explaining the clinical overlap between LLD and AD [19].”
BackgroundSelf-citationChanges in synaptic density in the subacute phase after ischemic stroke: A 11C-UCB-J PET/MR study
Michiels, L., Mertens, N., Thijs, L., Radwan, A., Sunaert, S., Vandenbulcke, M., Verheyden, G., Koole, M., Van Laere, K., & Lemmens, R. (2022) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x211047759 · Cited by 27 · cited 1×
“The centrum semiovale served as a reference region to calculate SUVR images (see Michiels et al. [32]. for the delineation method) maps after excluding any white matter lesions from the reference region (see MR acquisition for delineation method) [32, 33].”
MethodSelf-citationEmsell, L., Laroy, M., Cauwenberge, M. G. A. V., Casteele, T. V., Vansteelandt, K., Laere, K. V., Sunaert, S. G., den Stock, J. V., Bouckaert, F., & Vandenbulcke, M. (2021) · BMC Psychiatry · doi:10.1186/s12888-021-03063-y · Cited by 18 · cited 1×
“All participants from the ongoing Leuven Late Life depression study (see [23] for detailed information regarding sample size and recruitment) enrolled before November 2022 were included.”
BackgroundSelf-citationHalff, E. F., Cotel, M.-C., Natesan, S., McQuade, R., Ottley, C. J., Srivastava, D. P., Howes, O. D., & Vernon, A. C. (2021) · Behavioural Brain Research · doi:10.1016/j.bbr.2021.113203 · Cited by 18
Emsell, L., Vanhaute, H., Vansteelandt, K., Winter, F. D., Christiaens, D., den Stock, J. V., Vandenberghe, R. R., Laere, K. V., Sunaert, S. G., Bouckaert, F., et al. (2022) · Psychiatry Research Neuroimaging · doi:10.1016/j.pscychresns.2022.111443 · Cited by 14
Self-citationValidation and test–retest repeatability performance of parametric methods for [11C]UCB-J PET
Tuncel, H., Boellaard, R., Coomans, E. M., Hollander-Meeuwsen, M. D., de Vries, E. F. J., Glaudemans, A. W. J. M., Feltes, P. K., García, D. V., Verfaillie, S. C. J., Wolters, E. E., et al. (2022) · EJNMMI Research · doi:10.1186/s13550-021-00874-8 · Cited by 9
Does Late-Life Depression Accelerate Aging?
Lavretsky, H. (2023) · The American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2023.01.002 · Cited by 2
Cited by
Structural neural plasticity evoked by rapid-acting antidepressant interventions
Liao, C., Dua, A. N., Wojtasiewicz, C., Liston, C. M., & Kwan, A. C. (2024) · Nature reviews. Neuroscience · doi:10.1038/s41583-024-00876-0 · Cited by 87
“Another study has detected no change in synaptic signal in individuals with late-life depression (over 60 years of age) being treated with first-line antidepressant medications relative to the healthy control group 125 .”
Wu, J., Qiu, P., & Li, Y. (2024) · Journal of Affective Disorders · doi:10.1016/j.jad.2024.08.184 · Cited by 14
Asch, R. H., Abdallah, C. G., Carson, R. E., & Esterlis, I. (2025) · Neuropsychopharmacology · doi:10.1038/s41386-024-01913-3 · Cited by 13
Depression in older adults and its associations with sleep and synaptic density
Didikoğlu, A., Guler, E. S., Turk, H. K., Can, K., Erim, A. N., Payton, A., Murgatroyd, C., Pakpahan, E., Minshull, J., Robinson, A., et al. (2024) · Journal of Affective Disorders · doi:10.1016/j.jad.2024.08.186 · Cited by 14
Steinacker, P., Werner, L., Tarabuko, A., Al-Ali, I., Mechawar, N., Pryce, C. R., Cattane, N., Poggi, G., Shweiki, M. R. A., Graf, H., et al. (2025) · BMJ Mental Health · doi:10.1136/bmjment-2025-301752 · Cited by 6
“15 Furthermore, synaptic loss has been proposed to lead to increased rather than decreased brain SNAP-25 levels in neurodegenerative diseases.”
Metadata
- Authors
- Vande Casteele, T., Laroy, M., Van Cauwenberge, M., Koole, M., Dupont, P., Sunaert, S., Van den Stock, J., Bouckaert, F., Van Laere, K., Emsell, L., & Vandenbulcke, M.
- Affiliations
- KU Leuven (BE)
- ORCID
- Venue
- Translational Psychiatry
- Published
- 2024-03-14
- Volume
- 14
- Issue
- 1
- Pages
- 145-145
- ISSN
- 2158-3188 (ISSN-L)
- PMC
- PMC10940592
- OpenAlex
- W4392811934
- Semantic Scholar
- c48442c832225a7c74755b677ce6b2a1b98e3b09
- Cited by
- 14
- References
- 64
- Citations by year
- 2026: 4 · 2025: 7 · 2024: 3
- FWCI
- 3.98
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Translational Psychiatry (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Lirias (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Fonds Wetenschappelijk Onderzoek (G0C0319N)
- KU Leuven (C24-18-095)
- Vlaamse regering
- Universitaire Ziekenhuizen Leuven, KU Leuven
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Keywords
- geriatric depression, synaptic density, SV2A, [11C]UCB-J, gray matter volume, hippocampus, prefrontal cortex, medial temporal lobe, PET/MR, Alzheimer's disease comparison, synaptic deficits
- MeSH terms
- Aged, Alzheimer Disease, Depression, Female, Hippocampus, Humans, Prefrontal Cortex, Positron-Emission Tomography
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-05, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-05 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (qwen3.8-omni-flash and gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.